| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PCLO |
| Uniprot No | Q9Y6V0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 85-423aa |
| 氨基酸序列 | MKKFRVSLVSKVGKQKYVDLNMLSDSENSQHLELHEPPKAVDKAKSPGVD PKQLAAELQKVSLQQSPLVLSSVVEKGSHVHSGPTSAGSSSVPSPGQPGS PSVSKKKHGSSKPTDGTKVVSHPITGEIQLQINYDLGNLIIHILQARNLV PRDNNGYSDPFVKVYLLPGRGAEYKRRTKHVQKSLNPEWNQTVIYKSISM EQLKKKTLEVTVWDYDRFSSNDFLGEVLIDLSSTAHLDNTPRWYPLKEQT ESIDHGKSHSSQSSQQSPKPSVIKSRSHGIFPDPSKDMQVPTIEKSHSSP GSSKSSSEGHLRSHGPSRSQSKTSVTQTHLEDAGAAIAAAEAAVQQLRIQ PSKRRK |
| 预测分子量 | 65 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PCLO重组蛋白的3篇参考文献的简要信息：
---
1. **文献名称**：*Piccolo, a novel component of the presynaptic cytoskeleton*
**作者**：Mukherjee, K. et al.
**摘要**：该研究首次报道了PCLO(Piccolo)蛋白作为突触前活性区的重要支架蛋白，通过重组蛋白技术解析了其多个结构域(如PDZ和C2A结构域)，揭示了其在突触囊泡释放和细胞骨架组织中的调控作用。
2. **文献名称**：*Structural basis of Piccolo interaction with the presynaptic cytomatrix protein Bassoon*
**作者**：Waites, C.L. et al.
**摘要**：利用重组表达的PCLO片段和Bassoon蛋白，研究通过体外结合实验和X射线晶体学阐明了两种蛋白间的相互作用机制，为突触前复合体组装提供了分子基础。
3. **文献名称**：*Recombinant PCLO domains reveal distinct functional roles in presynaptic assembly*
**作者**：Gundelfinger, E.D. et al.
**摘要**：通过表达PCLO的重组结构域(如N端锌指结构和C端PDZ结合区)，验证了不同结构域在突触前靶向定位和蛋白互作网络中的特异性功能，强调了其多结构域协同调控突触形成的特性。
---
注：以上文献为示例，实际文献需通过数据库(如PubMed、Web of Science)检索确认。
**Background of PCLO Recombinant Protein**
PCLO (Piccolo), encoded by the *PCLO* gene, is a presynaptic cytomatrix protein predominantly localized at the active zones of neurotransmitter release sites in neurons. It plays a critical role in regulating synaptic vesicle cycling, neurotransmission, and synaptic plasticity. Structurally, PCLO is a large multi-domain protein containing multiple C2 domains, zinc finger motifs, and a PDZ domain, which facilitate interactions with other synaptic proteins such as Bassoon, RIM, and calcium channels. These interactions help anchor synaptic vesicles and organize the presynaptic machinery essential for efficient exocytosis.
The recombinant PCLO protein is engineered *in vitro* using expression systems like *E. coli* or mammalian cells to produce specific domains or full-length variants for functional studies. Its recombinant form enables detailed biochemical and structural analyses, aiding in the exploration of its role in synaptic function and dysfunction. Research has linked PCLO mutations or dysregulation to neuropsychiatric disorders, including autism spectrum disorders, depression, and schizophrenia, highlighting its potential as a therapeutic target.
Additionally, PCLO recombinant proteins are utilized in assays to study calcium-dependent protein interactions, synaptic vesicle dynamics, and presynaptic assembly mechanisms. They also serve as antigens for antibody development or tools in high-throughput drug screening. By providing a controlled and scalable source of PCLO, recombinant technology advances our understanding of synaptic biology and its implications in neurological diseases.
×
